特发性肺纤维化（IPF）是一种病因未明的慢性进展性纤维化肺疾病，目前尚无有效的治愈性药物。抗纤维化药物尼达尼布能延缓IPF患者肺功能下降，减少IPF急性加重的发生，已被国内外专家推荐用于IPF的治疗，尼达尼布于2017年9月在我国获得批准使用。

　　参考文献

[1] 杨厚宇,梁宗安.尼达尼布治疗特发性肺间质纤维化的研究进展[J].西部医学, 2017, 29(04): 578-581.

[2] 乙磺酸尼达尼布软胶囊说明书.

[3] SCHMID U，LIESENFELD K H，FLEURY A，et al．Populationpharmacokinetics of nintedanib，an inhibitor of tyrosine kinases, in patients with non- small cell lung cancer or idiopathic pulmonaryfibrosis[J]. Cancer Chemother Pharmacol, 2018, 81(1): 89-101.

[4] XING J，ZHANG J．Research progress of nintedanib in the treat-ment of idiopathic pulmonary fibrosi[J]．J China Pharm(中国药房), 2015, 26(29): 4174-4176．

[5] RODR GUEZ-PORTAL JA．Efficacy and safety of nintedanib forthe treatment of idiopathic pulmonary fibrosis: an update[J]. Drugs RD, 2018, 18(1): 19-25．[6] Sköld CM, Bendstrup E, Myllärniemi M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group[J]. J Intern Med. 2017, 281(2): 149-166.

出品：北京朝阳医院药事部

作者：胡海锦

审核：王华光